MYD88 and breast cancer: Activation of the TLR5/MyD88/NME3/NFκB signaling pathway enhances host immunity, enhances the clearance of tumor xenografts, and potentially augments the effectiveness of immunotherapy, prolonging survival in breast cancer patients (91).